louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01545128: Impact of Pulmonary Rehabilitation on Direct Healthcare Costs in Chronic Obstructive Pulmonary Disease (COPD)
Official title: A Retrospective Case-control Study Comparing the Direrct Healthcare Costs of Conventionally Managed COPD Patients With Those Who Have Completed a Pulmonary Rehabilitation Programme
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COPD
Keywords: COPD
Pulmonary rehabilitation
Lead sponsor: East and North Hertfordshire NHS Trust
Sponsor class: OTHER_GOV
First posted: 2012-03-06
Enrollment: 70
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: copd

Brief summary: The purpose of this study is to study the direct cost of illness study of COPD patients who participated in a Pulmonary rehabilitation program for 8 weeks.


Eligibility criteria: Inclusion Criteria:

* COPD

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00739128: Response to Hepatitis B Vaccine in Celiac Disease Patients
Official title: Intradermal Immunization Against Hepatitis B Virus in Celiac Disease- a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Celiac Disease
Keywords: celiac disease
hepatitis B vaccine
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2008-08-21
Enrollment: 210
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Celiac disease and infection with hepatitis B virus (HBV) are very prevalent worldwide and carry a high morbidity rate. It has been recently shown that patients with celiac disease very often fail to develop immunity after standard vaccination for HBV during infancy. In this study, we will evaluate whether a second vaccination series via a different route of administration (into the skin rather than the muscle) results in a better immunological response in celiac patients. Eligible patients will be randomized to receive a 3-dose vaccination series into the skin or to the muscle. Rate of responders and level of immunity will be compared. This study will facilitate better protection of celiac patients to this potentially deadly virus.


Eligibility criteria: Inclusion Criteria:

* Patients above 1 year of age with confirmed diagnosis of celiac disease by characteristic symptoms, serology and small bowel biopsy.
* Completion of the IM HBV vaccine series in infancy.
* HBsAb titer of ≤10mIU/mL at the time of enrollment.

Exclusion Criteria:

* Immunocompromised subjects or those receiving medications that may modulate or suppress the immune system (i.e. azathiopurine, 6-MP, steroids).
* Inability to obtain written informed consent and patients' assent, as appropriate by the maturity age.

Primary outcomes:
measure: 1. The primary endpoint of the study will be comparison of the geometric mean titers of anti-HBs between the intradermal and the intramuscular groups.
timeFrame: two years
Secondary outcomes:
measure: 1. Rate of responders four weeks after the completion of the series 2. Rate and characteristics of adverse drug reactions 3. Numerical increase in the antibodies titer before and after vaccination 4. Rate of responders in the cross over phase
timeFrame: two years
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: SZMC
Study officials:
affiliation: Shaheed Ziaur Rahman Medical College
name: Maskit Bar Meir, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Shaheed Ziaur Rahman Medical College
name: Ari Silbermintz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05361928: IS ElastomEtry Useful in Muscle Lesion evaluaTion-REPROducibility Study
Official title: IS ElastomEtry Useful in Muscle Lesion evaluaTion-REPROducibility Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Muscle Injury
Keywords: muscle
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2022-05-05
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients justifying an ultrasound evaluation for suspicion of muscle injury

Brief summary: Our objective is to evaluate the inter and intra observer reproducibility of the measure of elasticity using Acoustic Radiation Force Impulse (ARFI) ultrasonography of mucles of patients with and without hamstring injury.

76 patients will be evaluated cross sectionally twice by two ultrasonographists.

Detailed description: Muscle trauma mainly results from sporting activities and accounts for 10 to 55% of sports injuries.

Information on ARFI muscle trauma management is scarce. The present study sought to assess the initial ARFI characteristics of muscle in sports people with and without injury.

Our objective here is to evaluate the inter and intra observer reproducibility of the measure of elasticity using Acoustic Radiation Force Impulse (ARFI) ultrasonography of muscles of patients with and without hamstring injury.

76 patients will be evaluated cross sectionally twice by two ultrasonographists(and then we will evaluate the evolution after 3 months for patient with injury according to the ARFI results).

Eligibility criteria: Inclusion Criteria:

* Patients justifying an ultrasound evaluation for suspicion of muscle injury

Exclusion Criteria:

* Inflammatory muscle disease

Primary outcomes:
measure: Elasticity
timeFrame: Inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
References:
Clinical trial NCT03831828: Correlation of Gene Status and Clinical Outcomes in ESCC
Official title: Retrospective Study of Gene Status and Clinical Outcome of Esophageal Squamous Cell Carcinoma(ESCC).
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prognosis of Patients With ESCC
Lead sponsor: Hebei Medical University Fourth Hospital
Sponsor class: OTHER
Collaborators: name: OrigiMed
First posted: 2019-02-06
Enrollment: 46
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Taihang Mountain area population in northern China.

Brief summary: The incidence of esophageal squamous cell carcinoma is highly regional and familial. The current treatment plan is based on the stage and location of the tumor.By studying the relationship between the status of different genes and prognosis, it can help doctors to develop precise and individualized treatment plans.


Eligibility criteria: Inclusion Criteria:

* Esophageal cancer patients who underwent surgery treatment, and postoperative pathological diagnosis was squamous cell carcinoma. Patients with ESCC have complete clinical information.

Exclusion Criteria:

* Patients who also suffering from other tumors.

Primary outcomes:
measure: Gene test
timeFrame: 2019-2 to 2019-4
Secondary outcomes:
Other outcomes:
Locations:
city: Shijiazhuang
country: China
facility: Junfeng Liu
state: Hebei
Study officials:
References:
Clinical trial NCT00971061: Ahmed Glaucoma Valve and Single-Plate Molteno Implants in Treatment of Refractory Glaucoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Refractory Glaucoma
Keywords: Ahmed valve
single-plate Molteno implant
refractory glaucoma
surgical treatment
Lead sponsor: Vanak Eye Surgery Center
Sponsor class: OTHER
First posted: 2009-09-03
Enrollment: 72
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy and safety of the Ahmed valve implant (AVI) and the Molteno single-plate implant (MSPI) in eyes with refractory glaucoma during a follow-up period of 24 months.


Eligibility criteria: Inclusion Criteria:

* refractory glaucoma, defined as uncontrolled IOP despite maximal anti-glaucoma medication, previously failed nonseton surgical treatment, or a combination thereof.

Exclusion Criteria:

* age less than 40 years
* a visual acuity of no light perception
* lens opacity
* elevated IOP associated with silicone oil previous glaucoma drainage device implantation in the same eye
* previous cyclodestructive treatment
* increased risk of endophthalmitis posterior segment disorders
* pre-existing ocular comorbidities.

Primary outcomes:
measure: Intra Ocular pressure (IOP)
timeFrame: Month 24
Secondary outcomes:
measure: Intra Ocular pressure (IOP)
timeFrame: day 1,week 1, and months 1, 3, 6, 9, 12 and 18
measure: Changes in visual acuity
timeFrame: day 1,week 1, and months 1, 3, 6, 9, 12, 18, and 24.
measure: Number of anti-glaucoma medications
timeFrame: week 1, and months 1, 3, 6, 9, 12, 18, and 24
measure: Mean deviation of visual field,
timeFrame: week 1, and months 1, 3, 6, 9, 12, 18, and 24
measure: Rate of intra- and postoperative complications
timeFrame: week 1, and months 1, 3, 6, 9, 12, 18, and 24
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Vanak Eye Surgery Center
Study officials:
affiliation: Assistant Professor, Department of Ophthalmology, Imam Hussein Medical Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
name: Nader Nassiri, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical Researcher, Vanak Eye Surgery Center, Tehran, Iran
name: Nariman Nassiri, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: 4th-year Resident, Department of Ophthalmology, Imam Hussein Medical Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
name: Ghazal Kamali, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04761861: Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia
Official title: Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Schizophrenia
Dyslipidemias
Lead sponsor: Sadat City University
Sponsor class: OTHER
First posted: 2021-02-21
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of vildagliptin for antipsychotic-induced dyslipidemia.


Eligibility criteria: Inclusion Criteria:

* Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of Positive and Negative Syndrome Scale (PANSS)≤60.

Exclusion Criteria:

* liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus

Primary outcomes:
measure: low-density lipoprotein cholesterol
timeFrame: week 12
Secondary outcomes:
measure: high-density lipoprotein cholesterol
timeFrame: week 12
measure: Serum stem cell growth factor beta
timeFrame: week 12
measure: FAM19A5 serum level
timeFrame: 12 weeks
measure: TNF-alpha serum level
timeFrame: 12 weeks
measure: Adverse drug reactions
timeFrame: 12 weeks
Other outcomes:
measure: body mass index
timeFrame: 12 weeks
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Faculty of Pharmacy
state: Menoufia
Study officials:
References:
Clinical trial NCT01970761: Autologous Fat Graft Alleviate Scar Pain
Official title: Alleviation of Neuropathic Scar Pain With Autologous Fat Graft
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Scar
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2013-10-28
Enrollment: 36
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients received autologous fat grafting in scar areas

Brief summary: Traumatic wounds inflict small- and large-fiber sensory nerve damage, causing neuropathic pain in scar tissue. Autologous fat grafting has been clinically shown to improve scar quality, but scantly study has explored its effects on pain. The aim of the study was to survey its effect on pain.

Detailed description: Methods: From February 2008 and June 2013, a total of 36 patients received autologous fat grafting in scar areas. Patients who Douleur Neuropathique 4 Questions (scores \>4/10) were enrolled this study. The Visual Analogue Scale (VAS), and Neuropathic Pain Symptom Inventory (NPSI) were used to evaluate pain preoperatively and postoperatively after 1 week, 4 weeks, and 24 weeks. The mechanism of trauma, duration of allodynia, fat graft volume, and total follow-up time were recorded.

Eligibility criteria: Inclusion Criteria:

* February 2008 and June 2013, patients received autologous fat grafting in scar areas and also had pain over scar area before surgery

Exclusion Criteria:

* patients refused to participate the study

Primary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: preoperatively and postoperatively after 1 week, 4 weeks, and 24 weeks.
Secondary outcomes:
measure: Neuropathic Pain Symptom Inventory (NPSI)
timeFrame: preoperatively and postoperatively after 1 week, 4 weeks, and 24 weeks
Other outcomes:
Locations:
city: Kaohsiung City
country: Taiwan
facility: Kaohsiung Medical University Hospital
Study officials:
affiliation: Division of Plastic Surgery, Department of Surgery, Kaohsiung Medical University Hospital
name: shu-hung huang, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Division of Plastic Surgery, Department of Surgery, Kaohsiung Medical University Hospital
name: Chung-Sheng Lai, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02025361: Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy
Official title: Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Adenocarcinoma of Prostate
Keywords: prostate biopsy, local anesthesia, cancer detection rate.
Lead sponsor: Bagcilar Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2014-01-01
Enrollment: 422
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: DIAGNOSTIC

Brief summary: Transrectal ultrasound guided prostate biopsy (TRUS-Bx) is the gold standard method for prostat cancer diagnosis. Cancer detection rate is an important issue in TRUS-Bx. Effective biopsy protocol is necessary to enhance cancer detection rate during the procedure. Patient tolerance may improve the protocol effectiveness and quality.

Adequate patient tolerance with optimal local anesthesia may enhance cancer detection rate in TRUS-Bx.

Detailed description: In transrectal ultrasound guided prostate biopsy ultrasound's probe manipulation is necessary for effective biopsy. Patient discomfort and pain frequently occurs with manipulation of probe during transrectal ultrasound guided prostate biopsy and this situation may qualify of the achievement of this procedure.

In this study, we aimed to describe the impact of different two local anesthesia types on cancer detection rate in transrectal ultrasound guided prostate biopsy.

Eligibility criteria: Inclusion Criteria:

* Patients who underwent transrectal ultrasound guided prostate biopsy because of elevated serum PSA levels and/or suspicious rectal examination of prostate.

Exclusion Criteria:

* Previous TRUS-Bx and prostatic operations(TUR-P, open prostatectomy, etc..) history, treatment for prostate carcinoma, usage of finasteride and dutasteride.

Primary outcomes:
measure: cancer detection rate with anesthesia type
timeFrame: finally pathologic evaluation within 2-3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bagcilar Training and Research Hospital-Depertmant of urology
state: Bagcilar
Study officials:
affiliation: bagcilar training and research hospital-depertmant of urology
name: mustafa z temiz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00285961: Evaluation of Cork Splint Materials Instead of Plaster Splint for Children
Official title: Evaluation of Cork Splint Materials Instead of Plaster Splint for Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wrist Fractures
Forearm Fractures
Elbow Fractures
Ankle Fractures
Foot Fractures
Wounds and Injuries
Keywords: Fractures of the wrist, forearm, elbow, ankle, foot
Distortions of the wrist, elbow, ankle
Wounds without tendon injuries
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2006-02-02
Enrollment: 50
Sex: ALL
Minimum age (years): 3
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an evaluation of the functionality and added value of cork splint materials instead of a plaster splint for children (3-11 years old).


Eligibility criteria: Inclusion Criteria:

* Fractures of the wrist, forearm, elbow, ankle, foot
* Distortions of the wrist, elbow, ankle
* Wounds without tendon injuries

Primary outcomes:
measure: Functionality
measure: Added value
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Rene Verdonk, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00353561: Diabetes Mellitus and Vulvovaginal Candidiasis
Official title: Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus
Vulvovaginal Candidiasis
Lead sponsor: Indian Council of Medical Research
Sponsor class: OTHER_GOV
First posted: 2006-07-18
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical and mycological response to oral fluconazole and boric acid suppositories was assessed in patients with diabetes mellitus and vulvovaginal candidiasis.

Detailed description: A high proportion of vulvovaginal candidiasis is due to C.glabrata that responds poorly to fluconazole therapy. We assessed the clinical relief and mycological cure in response to oral fluconazole and boric acid suppositories in patients with diabetes mellitus and vulvovaginal candidiasis given in a Randomized trial. Fluconazole was given in standard oral single dose (150 mg) fluconazole and boric acid vaginal suppositories was given in dose of 600 mg/daily for 14 uninterrupted days.

Eligibility criteria: Inclusion Criteria:

* Consecutive patients with diabetes mellitus attending Endocrine OPD of All India Institute of Medical Sciences and in whom the diagnosis of vulvovaginal candidiasis was based on presence of clinical signs and symptoms and growth of Candida species on culture of high vaginal swab (HVS).

Exclusion Criteria:

* Patients with vaginal discharge in whom Candida growth was not detected on fungal culture were excluded.
* Subjects also excluded were those with pregnancy,
* Sexually inactive girls,
* Age \> 65 years, renal failure and steroid therapy.
* Patients who did not give consent for pelvic examination,
* Those who were treated for any kind of vaginal discharge during the past three months and who did not comply with boric acid therapy or did not report on 15th day for repeat examination excluded.

Primary outcomes:
measure: Mycological cure on the 15th day of therapy and defined as the absence of Candida growth on fungal culture of high vaginal swab
timeFrame: 15 days
Secondary outcomes:
measure: Relief in clinical symptoms and signs of vulvovaginal candidiasis including vaginal discharge, pruritus, burning sensation and vaginal congestion
timeFrame: 15 days
Other outcomes:
Locations:
city: Delhi
country: India
facility: Dr Ravinder Goswami
Study officials:
affiliation: All India Institute of Medical Sciences New Delhi, 110029, India
name: Ravinder Goswami, DM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01901861: Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes
Official title: Effect of a Single Dose of the DPP-4 Inhibitor on Islet Function After Igestion of a Standardized Mixed Meal in Subjects With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes
Keywords: GLP-1, GIP, DPP-4 inhibition, iset function
Lead sponsor: Lund University
Sponsor class: OTHER
First posted: 2013-07-17
Enrollment: 12
Sex: MALE
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL

Brief summary: study hypothesis to examine the acute effects on glycaemia and islet hormone secretion of increased levels of endogenous GLP-1 and GIP on islet cell function in men with type 2 diabetes. To this purpose, a standardized mixed meal test will be ingested with or without concomitant administration of sitagliptin (100mg).

Detailed description: In men subjects with type 2 diabetes treated with diet and exercise with or without metformin treatment as an antidiabetic agent, a standardized mixed meal test will be served with or without administration of sitagliptin (100mg).

Eligibility criteria: Inclusion Criteria:

* Caucasian men with type 2 diabetes diagnosed according to ICD10
* Ongoing treatment with life style adjustment or life style adjustment together with metformin as oral antidiabetic. Metformin therapy should not exceed 2 grams daily
* Age 20-75 years
* HbA1c ≤80 mmol/mol
* BMI: 20-40 kg/m2

Exclusion Criteria:

* Liver disease or ALAT three times above upper reference range
* Diabetic nephropathy (GFR \< 50 mL/min/1.73 m2 or albuminuria)
* Proliferative diabetic retinopathy
* Treatment with any glucose-lowering medication except metformin
* Previous myocardial infarction, coronary heart disease or insatiable angina pectoris in the last 6 months.
* Previous surgery on the gastrointestinal tract
* Larger surgical intervention during the last 12 weeks
* Treatment with oral steroids or thiazide diuretics
* Treatment with digoxin
* Smokers
* Participation in another study the last 4 weeks
* Paracetamol intolerance

Primary outcomes:
measure: Release of incretins hormones
timeFrame: 300 min
Secondary outcomes:
Other outcomes:
Locations:
city: Lund
country: Sweden
facility: Department of Clinical Science Lund,Lund University
Study officials:
affiliation: Lund University
name: Bo Ahren, Professor
role: PRINCIPAL_INVESTIGATOR
References: